Vol 25, No 4 (2018)
Original articles — Clinical cardiology
Published online: 2017-04-10

open access

Page views 2944
Article views/downloads 1468
Get Citation

Connect on Social Media

Connect on Social Media

Clinical profile and management of outpatients with non-ischemic and non-hypertensive systolic heart failure: Analysis of the Polish DATA-HELP registry

Justyna M. Sokolska12, Beata Kurian, Waldemar Banasiak, Ewa A. Jankowska234, Piotr Ponikowski25
Pubmed: 28394012
Cardiol J 2018;25(4):512-520.


Background: Although coronary artery disease and arterial hypertension are the most common etiologies underlying heart failure (HF), there are still many patients present with non-ischemic and non-hypertensive HF whose management remains very challenging. In this research study the clinical profile and applied treatment of patients with HF without coronary artery disease or hypertension versus patients with known etiology of HF (ischemic/hypertensive) were compared.

Methods: Clinical data about 5563 patients with stable systolic HF were obtained from prospective multicenter DATA-HELP registry performed between October and December 2009 in ambulatory clinics in Poland, in which 500 cardiologists and 290 general practitioners participated.

Results: Heart failure of non-ischemic and non-hypertensive etiology which affected 10% of all patients and was particularly frequent in younger patients, both in women: < 50 years old 42%; 50–65 years old 12%; > 65 years old 7%; and men: < 50 years old 47%; 50–65 years old 10%; > 65 years old 5%; p < 0.0001. Patients with non-ischemic and non-hypertensive HF were characterized by younger age, fewer co-morbidities, shorter duration of HF and, surprisingly, more advanced HF. Patients in this group were less likely to have received life-prolonging treatment in HF recommended by European Society of Cardiology (ESC) and more often required symptomatic management. Similarly, they were more likely to have implanted CRT-D and ICD.

Conclusions: Heart failure of non-ischemic and non-hypertensive origin affects particularly young patients. These patients, despite suffering from more advanced HF are not optimally managed according to ESC guidelines.

Article available in PDF format

View PDF Download PDF file


  1. McMurray JJV, Adamopoulos S, Anker SD, et al. Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology, ESC Committee for Practice Guidelines. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2012; 14(8): 803–869.
  2. McMurray JJ. Heart failure: Epidemiology, aetiology, and prognosis of heart failure. Heart. 2000; 83(5): 596–602.
  3. Cowie MR, Wood DA, Coats AJ, et al. Incidence and aetiology of heart failure; a population-based study. Eur Heart J. 1999; 20(6): 421–428.
  4. Linhart A, Elliott PM. The heart in Anderson-Fabry disease and other lysosomal storage disorders. Heart. 2007; 93(4): 528–535.
  5. Quarta CC, Kruger JL, Falk RH. Cardiac Amyloidosis. Circulation. 2012; 126(12): e178–e182.
  6. Gheorghiade M, Vaduganathan M, Fonarow GC, et al. Rehospitalization for heart failure: problems and perspectives. J Am Coll Cardiol. 2013; 61(4): 391–403.
  7. Giamouzis G, Kalogeropoulos A, Georgiopoulou V, et al. Hospitalization epidemic in patients with heart failure: risk factors, risk prediction, knowledge gaps, and future directions. J Card Fail. 2011; 17(1): 54–75.
  8. McLaren DP, Jones R, Plotnik R, et al. Prior hospital admission predicts thirty-day hospital readmission for heart failure patients. Cardiol J. 2016; 23(2): 155–162.
  9. Tokatli A, Ural D. Previous hospitalizations predict both hospital readmissions and mortality in patients with heart failure. Cardiol J. 2016; 23(2): 224–224.
  10. Wichmann BA, Hill ID. Generating good pseudo-random numbers. Computational Statistics & Data Analysis. 2006; 51(3): 1614–1622.
  11. Jankowska EA, Kalicinska E, Drozd M, et al. Comparison of clinical profile and management of outpatients with heart failure with reduced left ventricular ejection fraction treated by general practitioners and cardiologists in contemporary Poland: the results from the DATA-HELP registry. Int J Cardiol. 2014; 176(3): 852–858.
  12. Rywik TM, Rywik SL, Korewicki J, et al. Management of heart failure patients in Poland. Eur J Heart Fail. 2002; 4(2): 215–219.
  13. Howell EH, Cameron SJ. Neprilysin inhibition: A brief review of past pharmacological strategies for heart failure treatment and future directions. Cardiol J. 2016; 23(6): 591–598.
  14. Kim EK, Chang SA, Choi JO, et al. Concordant and discordant cardiac magnetic resonance imaging delayed hyperenhancement patterns in patients with ischemic and non-ischemic cardiomyopathy. Korean Circ J. 2016; 46(1): 41–47.
  15. Mavrogeni S, Markousis-Mavrogenis G, Markussis V, et al. The Emerging Role of Cardiovascular Magnetic Resonance Imaging in the Evaluation of Metabolic Cardiomyopathies. Horm Metab Res. 2015; 47(9): 623–632.
  16. Valbuena-López S, Hinojar R, Puntmann VO. Cardiovascular magnetic resonance in cardiology practice: A concise guide to image acquisition and clinical interpretation. Rev Esp Cardiol (Engl Ed). 2016; 69(2): 202–210.
  17. Saeed M, Van TuA, Krug R, et al. Cardiac MR imaging: current status and future direction. Cardiovasc Diagn Ther. 2015; 5(4): 290–310.
  18. Won E, Donnino R, Srichai MB, et al. Diagnostic accuracy of cardiac magnetic resonance imaging in the evaluation of newly diagnosed heart failure with reduced left ventricular ejection fraction. Am J Cardiol. 2015; 116(7): 1082–1087.
  19. Bejar D, Colombo PC, Latif F, et al. Infiltrative cardiomyopathies. Clin Med Insights Cardiol. 2015; 9(Suppl 2): 29–38.
  20. Gonzalez JA, Kramer CM. Role of imaging techniques for diagnosis, prognosis and management of heart failure patients: cardiac magnetic resonance. Curr Heart Fail Rep. 2015; 12(4): 276–283.
  21. Kuruvilla S, Adenaw N, Katwal AB, et al. Late gadolinium enhancement on cardiac magnetic resonance predicts adverse cardiovascular outcomes in nonischemic cardiomyopathy: a systematic review and meta-analysis. Circ Cardiovasc Imaging. 2014; 7(2): 250–258.
  22. Dominguez F, Kühl U, Pieske B, et al. Update on myocarditis and inflammatory cardiomyopathy: Reemergence of endomyocardial biopsy. Rev Esp Cardiol (Engl Ed). 2016; 69(2): 178–187.
  23. Bennett MK, Gilotra NA, Harrington C, et al. Evaluation of the role of endomyocardial biopsy in 851 patients with unexplained heart failure from 2000-2009. Circ Heart Fail. 2013; 6(4): 676–684.
  24. Berthelot-Richer M, O'Connor K, Bernier M, et al. When should we consider the diagnosis of giant cell myocarditis? Revisiting "classic" echocardiographic and clinical features of this rare pathology. Exp Clin Transplant. 2014; 12(6): 565–568.
  25. Loh JC, Creaser J, Rourke DA, et al. Temporal trends in treatment and outcomes for advanced heart failure with reduced ejection fraction from 1993-2010: findings from a university referral center. Circ Heart Fail. 2013; 6(3): 411–419.
  26. Maggioni AP, Anker SD, Dahlström U, et al. Heart Failure Association of the ESC. Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail. 2013; 15(10): 1173–1184.
  27. Sosnowska-Pasiarska B, Bartkowiak R, Wożakowska-Kapłon B, et al. Population of Polish patients participating in the Heart Failure Pilot Survey (ESC-HF Pilot). Kardiol Pol. 2013; 71(3): 234–240.
  28. van Veldhuisen DJ, Maass AH, Priori SG, et al. Implementation of device therapy (cardiac resynchronization therapy and implantable cardioverter defibrillator) for patients with heart failure in Europe: changes from 2004 to 2008. Eur J Heart Fail. 2009; 11(12): 1143–1151.
  29. Maggioni AP, Dahlström U, Filippatos G, et al. Heart Failure Association of the European Society of Cardiology (HFA), Heart Failure Association of ESC (HFA). EURObservational Research Programme: the Heart Failure Pilot Survey (ESC-HF Pilot). Eur J Heart Fail. 2010; 12(10): 1076–1084.
  30. McMurray JJV, Packer M, Desai AS, et al. PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014; 371(11): 993–1004.